Developer docs
API playgroundTry for free, no card

Search company profiles

TxCell

Full company profile

uuid0006lo1

Namestring
TxCell
Websiteurl
txcell.com
Company typeenum
Private
Founded yearint
2001
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersValbonne, France
HQ citystring
Valbonne
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
cell-based immunotherapy, inflammatory disease therapeutics, regulatory T-cell therapy, cell therapy development, biologics manufacturing
Industry3 codes
1Cell Therapy Developers (Autologous)
CodeHLAAABAAPrimaryYes
2Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
CodeHLAAABAHPrimaryNo
3Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring)
CodeHLAAABAJPrimaryNo
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cell-based Immunotherapy
No data
Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

TxCell develops cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases. The company focuses on creating therapeutic products derived from engineered immune cells, with operations centered in Valbonne, France. It functions as a clinical-stage biotechnology company working on novel cellular therapies.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Cell-based immuno-therapies
CategoryCell-based Immunotherapy
Description

Therapeutic products based on engineered immune cells (such as regulatory T-cells) intended for the treatment of severe chronic inflammatory diseases. Targeted at healthcare providers and patients with chronic inflammatory conditions, developed as clinical-stage biological products.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
1Sangamo Therapeutics
TypeDirect peer
Description

Gene and cell therapy developer historically active in Treg and engineered cell therapy programs. Sangamo's prior acquisition activity in the Treg space (including its 2018 transaction involving TxCell) makes it a direct comparable in autologous cell-based immunotherapy.

2Quell Therapeutics
TypeDirect peer
Description

UK-based clinical-stage biotech developing engineered regulatory T-cell (Treg) therapies for autoimmune and inflammatory diseases. Directly comparable to TxCell on therapeutic modality (Tregs), indication focus, and autologous cell engineering approach.

3Sonoma Biotherapeutics
TypeDirect peer
Description

Clinical-stage Treg cell therapy company developing antigen-specific regulatory T-cell therapies for autoimmune and inflammatory diseases. Highly comparable to TxCell in modality, target indications, and autologous cell engineering approach.

4Coya Therapeutics
TypeDirect peer
Description

Clinical-stage biotech developing Treg-focused therapies (including ex vivo expanded Treg products) for neurodegenerative and inflammatory diseases. Comparable in autologous Treg modality and inflammation/autoimmune indication focus.

5Cellectis
TypeDirect peer
Description

French clinical-stage cell therapy company developing allogeneic CAR-T and gene-edited cell therapies. Comparable as a fellow French-headquartered cell therapy developer with overlapping investor base and platform technology focus.

6Adaptimmune Therapeutics
TypeDirect peer
Description

Clinical-stage cell therapy company developing engineered T-cell therapies (SPEAR T-cells) for solid tumors. Comparable as a publicly listed, small-cap cell therapy developer with similar headcount scale and clinical-stage profile.

7Allogene Therapeutics
TypeDirect peer
Description

Clinical-stage allogeneic CAR-T cell therapy developer. Comparable as a publicly listed cell therapy company targeting similar clinical development stages and inflammatory/oncology indications.

8Novartis
TypeBroad incumbent
Description

Global pharmaceutical leader with Kymriah, the first FDA-approved CAR-T cell therapy. Comparable as the dominant large-cap incumbent in cell therapy, setting manufacturing, regulatory, and commercial benchmarks relevant to TxCell's cell therapy development.

9Gilead Sciences (Kite Pharma)
TypeBroad incumbent
Description

Major cell therapy player through Kite Pharma (Yescarta, Tecartus). Comparable as a large-cap incumbent in autologous cell therapy with established commercial manufacturing infrastructure that benchmarks TxCell's eventual scale-up path.

10Tract Therapeutics
TypeEmerging player
Description

Emerging cell therapy developer with focus on engineered cell therapies for immune-mediated diseases. Comparable as an early-stage competitor in the cell-based treatment of inflammatory/autoimmune conditions.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TxCell

Cell-based Immunotherapytxcell.com

TxCell firmographics

Firmographics
Name
TxCell
Website
https://txcell.com
Company type
Private
Founded year
2001
Headcount range
51–100 employees
Ownership category
akta.pro rank

TxCell industry classification

Industry
Product category
Cell-based Immunotherapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro primary industry
Cell Therapy Developers (Autologous) (HLAAABAA)
akta.pro secondary industries
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH), Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring) (HLAAABAJ)

Keywords

  • Cell-based immunotherapy
  • Inflammatory disease therapeutics
  • Regulatory T-cell therapy
  • Cell therapy development
  • Biologics manufacturing

Where TxCell is headquartered

Location

Headquarters

HQ city
Valbonne
HQ country
France
HQ region
Europe

Markets served

TxCell business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

TxCell product offering

Product offering

Core offering

TxCell develops cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases. The company focuses on creating therapeutic products derived from engineered immune cells, with operations centered in Valbonne, France. It functions as a clinical-stage biotechnology company working on novel cellular therapies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cell-based immuno-therapies Therapeutic products based on engineered immune cells (such as regulatory T-cells) intended for the treatment of severe chronic inflammatory diseases. Targeted at healthcare providers and patients with chronic inflammatory conditions, developed as clinical-stage biological products.

Companies that use TxCell

Customer profile

Ideal customer profiles1 record

TxCell technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

TxCell partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights3 records

TxCell competitors and assessment

Company assessment

Direct peers

  • Sangamo Therapeutics: Gene and cell therapy developer historically active in Treg and engineered cell therapy programs. Sangamo's prior acquisition activity in the Treg space (including its 2018 transaction involving TxCell) makes it a direct comparable in autologous cell-based immunotherapy.
  • Quell Therapeutics: UK-based clinical-stage biotech developing engineered regulatory T-cell (Treg) therapies for autoimmune and inflammatory diseases. Directly comparable to TxCell on therapeutic modality (Tregs), indication focus, and autologous cell engineering approach.
  • Sonoma Biotherapeutics: Clinical-stage Treg cell therapy company developing antigen-specific regulatory T-cell therapies for autoimmune and inflammatory diseases. Highly comparable to TxCell in modality, target indications, and autologous cell engineering approach.
  • Coya Therapeutics: Clinical-stage biotech developing Treg-focused therapies (including ex vivo expanded Treg products) for neurodegenerative and inflammatory diseases. Comparable in autologous Treg modality and inflammation/autoimmune indication focus.
  • Cellectis: French clinical-stage cell therapy company developing allogeneic CAR-T and gene-edited cell therapies. Comparable as a fellow French-headquartered cell therapy developer with overlapping investor base and platform technology focus.
  • Adaptimmune Therapeutics: Clinical-stage cell therapy company developing engineered T-cell therapies (SPEAR T-cells) for solid tumors. Comparable as a publicly listed, small-cap cell therapy developer with similar headcount scale and clinical-stage profile.
  • Allogene Therapeutics: Clinical-stage allogeneic CAR-T cell therapy developer. Comparable as a publicly listed cell therapy company targeting similar clinical development stages and inflammatory/oncology indications.

Broad incumbents

  • Novartis: Global pharmaceutical leader with Kymriah, the first FDA-approved CAR-T cell therapy. Comparable as the dominant large-cap incumbent in cell therapy, setting manufacturing, regulatory, and commercial benchmarks relevant to TxCell's cell therapy development.
  • Gilead Sciences (Kite Pharma): Major cell therapy player through Kite Pharma (Yescarta, Tecartus). Comparable as a large-cap incumbent in autologous cell therapy with established commercial manufacturing infrastructure that benchmarks TxCell's eventual scale-up path.

Emerging players

  • Tract Therapeutics: Emerging cell therapy developer with focus on engineered cell therapies for immune-mediated diseases. Comparable as an early-stage competitor in the cell-based treatment of inflammatory/autoimmune conditions.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

TxCell financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TxCell leadership team

Management profile

Number of profiles

Profiles1 record

TxCell funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TxCell M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TxCell

What does TxCell do?

TxCell develops cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases. The company focuses on creating therapeutic products derived from engineered immune cells, with operations centered in Valbonne, France. It functions as a clinical-stage biotechnology company working on novel cellular therapies.

When was TxCell founded?

TxCell was founded in 2001. It employs 51 to 100 people.

Where is TxCell based?

TxCell is headquartered in Valbonne, France, in the Europe region.

Who are TxCell's main competitors?

Direct peers on record are Sangamo Therapeutics, Quell Therapeutics, Sonoma Biotherapeutics, Coya Therapeutics, Cellectis, Adaptimmune Therapeutics and Allogene Therapeutics. Broad incumbents are Novartis and Gilead Sciences (Kite Pharma). Tract Therapeutics is listed as an emerging player.

Does TxCell have an API?

No public API is recorded for TxCell.

What industry is TxCell in?

TxCell's product category is Cell-based Immunotherapy. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAAABAH, Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSangamo Announces Completion Of TxCell AcquisitionSangamo Therapeutics announced the completion of its acquisition of TxCell, SA, a French biotech company specializing in CAR-Treg cell therapies, with TxCell becoming a wholly-owned subsidiary delisted from the French stock market on December 3, 2018. Sangamo acquired 95.71% of TxCell through a simplified tender offer finalized on November 23, 2018, followed by a squeeze-out procedure on November 29 to acquire all remaining shares. The acquisition combines Sangamo's zinc finger nuclease gene editing technology with TxCell's CAR-Treg platform to develop therapies for autoimmune and inflammatory disorders, with plans to submit a clinical trial authorization application in Europe in 2019.PR NewswireSangamo and TxCell announce the completion of the acquisition by Sangamo of majority of TxCell ordinary sharesSangamo Therapeutics completed its acquisition of approximately 53% of TxCell's share capital and voting rights at €2.58 per share in cash on October 1, 2018. Sangamo will file a simplified tender offer for all remaining TxCell shares and expects to launch a squeeze-out procedure to delist TxCell once it obtains at least 95% ownership. TxCell will operate as a French-based subsidiary while Sangamo plans to initiate the first CAR-Treg clinical trial for solid organ transplant rejection in 2019.BioProcess InternationalSangamo Bets on CAR-Treg Through $84m TxCell AcquisitionSangamo Therapeutics has agreed to acquire French biotech TxCell for approximately €72 million (US$84 million) to bolster its pipeline with cellular immunotherapies based on regulatory T lymphocytes. The acquisition allows TxCell to advance candidates like TX200 toward clinical validation and commercialization, providing capital that was previously inaccessible as a standalone business. This deal positions Sangamo in the emerging field of CAR-Tregs for transplantation and autoimmune diseases using its Zinc Finger Nuclease technology.BioPharma DiveSangamo to buy TxCell, cell therapy tech in $84M dealSangamo Therapeutics agreed to acquire French biotech TxCell for $84 million to expand its cell therapy research into immunological diseases using CAR-modified regulatory T cells. The acquisition will see TxCell operate as a subsidiary in Valbonne, France, with the deal expected to close in the fourth quarter. This move allows Sangamo to leverage TxCell's preclinical pipeline, which includes a candidate set for Phase 1/2 testing next year.PR NewswireEdison Issues Outlook on TxCell (TXCL)Edison Investment Research issued an analyst outlook on TxCell (TXCL), revising the company's net present value to €74m (€3.75/share undiluted, €2.83/share diluted), down from approximately €76m, reflecting reduced probability for the Ovasave Crohn's disease program. TxCell's CAR-modified regulatory T-cell platform is progressing with four indications in preclinical development and a first CAR Treg trial for transplant rejection anticipated by late 2018. The Ovasave probability was reduced from 29.7% to 18%, lowering its NPV contribution from €170m to €90m, while CAR Treg project valuations were raised from €22m to €30m.PR NewswireEdison Issues Initiation on TxCellEdison Investment Research has issued an initiation coverage report on TxCell, a biotech company developing regulatory T-cell (Treg) therapies for inflammatory and autoimmune disorders, with Ovasave in a Phase IIb study for refractory Crohn's disease. The report assigns TxCell an indicative pre-funding value of €7.08 per share, requiring approximately €27 million in additional capital through late 2017, with a potential market value exceeding €300 million if Phase IIb data is positive and a Phase III partnership deal of at least €175 million materializes by 2018.GlobeNewswireOrgenesis Subsidiary MaSTherCell to Manufacture TxCell's Lead Product Ovasave for Multi-National Phase 2b TrialOrgenesis subsidiary MaSTherCell signed a memorandum of understanding with France-based TxCell to manufacture clinical batches of Ovasave, a T-cell therapy for Crohn's disease. The batches will support TxCell's ongoing Phase 2b trial CATS29, with first batches possible in Q2 2016. The trial includes 160 patients across 30 sites in six countries.FinSMEsTxCell Raises €12.4M in Third FinancingTxCell SA raised €12.4M in a third financing, with €6M from InnoBio fund and existing investors. The capital will develop Ovasave, a Treg cell-based immunotherapy for Crohn's disease in refractory patients. The company has raised €23.9M since 2004.